Buy Akorn (AKRX) on Sell-Off, Guggenheim Says

Go back to Buy Akorn (AKRX) on Sell-Off, Guggenheim Says

Akorn (AKRX) Appoints Two New EVPs, One Corp. Controller

April 27, 2015 8:30 AM EDT

Akorn (NASDAQ: AKRX) announced the following recent executive appointments for roles on the Akorn management team:

Jonathan Kafer, former Vice President, Account Management at Allergan, Inc., was appointed Executive Vice President, Sales and Marketing. In this newly-created role, Mr. Kafer will oversee all commercial functions for all of Akorn's business units. Mr. Kafer will also play an integral role in strategic market and product portfolio considerations. At Allergan, Mr. Kafer was responsible for all trade activity within Allergan's wholesale, retail specialty pharmacy, e-Solutions and managed market channels for... More

Piper Jaffray Downgrades Akorn (AKRX) to Neutral

April 27, 2015 6:53 AM EDT

Piper Jaffray downgraded Akorn (NASDAQ: AKRX) from Overweight to Neutral with a price target of $53.00 (from $66.00) saying another restatement adds to credibility issues.

David Amsellem commented, "Akorn announced that it will need to further restate financials for 2014. The latest developments are particularly... More

Akorn (AKRX) Names Terry Rappuhn to Board

April 24, 2015 4:15 PM EDT

Akorn, Inc. (Nasdaq: AKRX) today announced the appointment of Terry Allison Rappuhn to its Board of Directors and the Board's Audit Committee, effective immediately. In her accomplished career spanning over three decades working with and for public corporations, Ms. Rappuhn has helped rapidly growing companies build infrastructure, processes and teams during periods of transition.

"Terry is a terrific addition to our Board of Directors, and we... More